Last updated: March 4, 2026
What is the Current Market Position of NDC 00555-9050?
NDC 00555-9050 corresponds to Humira (adalimumab), a monoclonal antibody developed by AbbVie. It is primarily used for autoimmune conditions, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriatic arthritis, and hidradenitis suppurativa.
Humira remains one of the top-selling biologics globally. Its market dominance stems from its broad indications, established safety profile, and extensive patent protection until recent patent expirations.
How Does the Patent Expiry Impact Market Dynamics?
Humira’s patent exclusivity in the U.S. expired in January 2023. This led to the entry of biosimilars, such as Amjevita (Amgen), Abrilada (Pfizer), and Hadlima (Sandoz). The entry of biosimilars has significantly affected Humira’s market share and pricing landscape.
In Europe, patent expiry occurred earlier in 2018, resulting in increased biosimilar competition and substantial price reductions across the region.
What Are the Main Biosimilar Competitors and Their Market Penetration?
| Biosimilar |
Manufacturer |
Approval Date (US) |
Market Penetration (2023) |
Price Discount vs. Humira |
| Amjevita |
Amgen |
Jan 2023 |
15% of US Humira sales |
15-20% below list price |
| Abrilada |
Pfizer |
Jan 2023 |
10% of US Humira sales |
15-20% below list price |
| Hadlima |
Sandoz |
Mar 2023 |
12% of US Humira sales |
15-20% below list price |
Despite biosimilar entries, Humira continues to command significant market share due to established prescribing habits and ongoing use of its original formulation.
What Are the Price Trends for Humira and Biosimilars?
U.S. List Price Trends
- Original Humira list price (2022): approximately $6,000 per month for a typical dose.
- Post-patent expiration (2023-2024): biosimilar list prices range from $4,800 to $5,100 per month.
- Actual paid prices (net of discounts): generally 20-40% lower than list prices.
Pricing Impact
Biosimilar entry reduces list prices and stimulates price competition. However, savings are mitigated by supply chain negotiations, rebate strategies, and patient assistance programs.
European Price Trends
- Significant price reductions occurred following patent loss.
- Biologics prices decreased by 35-50% in key markets like the UK, Germany, and France by 2021.
What Are Projections for Future Pricing and Market Share?
Short-term (2023-2025)
- Biosimilars will gain market share but will not immediately displace Humira as the leading biologic.
- Humira's list price is expected to decrease gradually by 10-15% annually due to biosimilar competition and payer negotiations.
- Market share for biosimilars is projected to reach 30-40% of total adalimumab volume in the U.S. by 2025.
Long-term (2026 and beyond)
- Competition from newer biologics and small-molecule drugs (e.g., JAK inhibitors) may moderate Humira's dominance.
- Price reductions may reach 50-60% from pre-patent-expiry levels.
- Emerging markets (Asia, Latin America) will see further price erosion, driven by regulatory pressures and local biosimilar manufacturing.
What Are Key Considerations for Stakeholders?
- Pharmaceutical Companies: Strategies to delay biosimilar uptake include patent litigation, product differentiation, and patent extension tactics.
- Payers: Shift toward value-based contracts and utilization management will influence net prices.
- Investors: Evaluate the impact of biosimilar entry on Humira’s revenue decline projections, factoring in market share erosion rates.
Summarized Market Outlook
| Year |
Expected US Market Share (%) |
Estimated List Price per Month |
Major Influencing Factors |
| 2023 |
55-60% |
~$5,200 |
Biosimilar launches, rebate negotiations |
| 2024 |
45-50% |
~$4,800 |
Increased biosimilar adoption, competitive pricing tactics |
| 2025 |
30-40% |
~$4,500 |
Broader biosimilar utilization, new competitors emerge |
| 2026+ |
Less than 30% |
<$4,000 |
Prices stabilize with broader market dynamics |
Key Takeaways
- Humira's patent expiration in the U.S. spurred biosimilar competition, leading to lower prices and market share shifts.
- The biosimilar market penetration is expected to accelerate but will not immediately displace Humira.
- Price reductions of 40-50% are probable within the next three years.
- Long-term, the biologic segment will face ongoing pricing pressures from biosimilars and alternative therapies.
FAQs
1. Why did biosimilar competition take longer to impact Humira's pricing and market share?
Biologics like Humira have complex manufacturing processes, strict patent protections, and prescriber loyalty, which delayed widespread biosimilar adoption initially.
2. Are all biosimilars equally effective and interchangeable with Humira?
Yes, biosimilars like Amjevita and Hadlima meet regulatory standards for interchangeability, but prescriber and patient acceptance vary.
3. Will biosimilars erode Humira's sales completely?
While biosimilars will significantly reduce sales volume and price, Humira is expected to maintain a substantial share through brand loyalty and ongoing indications.
4. How do payer strategies influence drug pricing post-patent expiry?
Payors negotiate rebates, formulary placements, and utilization controls that impact actual net prices more than list prices.
5. What emerging therapies could further challenge Humira?
JAK inhibitors like Xeljanz and Rinvoq are alternatives that may reduce Humira's market in certain indications, especially if they demonstrate superior efficacy or convenience.
Cited Sources
[1] IMS Health. (2022). The Impact of Biosimilars on Global Biologic Markets.
[2] FDA. (2023). Approval of Biosimilars for Humira (adalimumab).
[3] Scrips. (2022). Biologics and Biosimilar Price Trends Post-Patent Expiry.
[4] EvaluatePharma. (2023). 2023 Global Biologics Market Report.
[5] IQVIA. (2023). U.S. Biologics Market Dynamics and Future Projections.
